Oncoxin-Viusid(®) may improve quality of life and survival in patients with hormone-refractory prostate cancer undergoing onco-specific treatments

The aim of the present study was to identify the efficacy and safety of Oncoxin-Viusid (OV) as a supportive treatment for patients with prostate cancer (PCA). A prospective, non-randomised, open-label phase II clinical trial, including 25 patients with hormone-refractory PCA (HRPC) was conducted at...

Descripción completa

Detalles Bibliográficos
Autores principales: Fundora Ramos, Mercedes Iveet, Maden, Lourdes Boulet, Casanova, Fernando Oriol, Cruz, Frank Hernández, Reyes, Carina Salgado, Gato, Adalberto Hernandez, Lyncon, Israel Benítez, González, Etna Vega, Morales, Katia Palau, Lence, Juan J., Sanz, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678621/
https://www.ncbi.nlm.nih.gov/pubmed/33235733
http://dx.doi.org/10.3892/mco.2020.2167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678621/
https://www.ncbi.nlm.nih.gov/pubmed/33235733
http://dx.doi.org/10.3892/mco.2020.2167

Ejemplares similares